APA

Hong D. S., Hui D., Bruera E., Janku F., Naing A., Falchook G. S., Piha-Paul S., Wheler J. J., Fu S., Tsimberidou A. M., Stecher M., Mohanty P., Simard J. & Kurzrock R. (20140623). MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. : The Lancet. Oncology.

Chicago

Hong David S, Hui David, Bruera Eduardo, Janku Filip, Naing Aung, Falchook Gerald S, Piha-Paul Sarina, Wheler Jennifer J, Fu Siqing, Tsimberidou Apostolia M, Stecher Michael, Mohanty Prasant, Simard John and Kurzrock Razelle. 20140623. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. : The Lancet. Oncology.

Harvard

Hong D. S., Hui D., Bruera E., Janku F., Naing A., Falchook G. S., Piha-Paul S., Wheler J. J., Fu S., Tsimberidou A. M., Stecher M., Mohanty P., Simard J. and Kurzrock R. (20140623). MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. : The Lancet. Oncology.

MLA

Hong David S, Hui David, Bruera Eduardo, Janku Filip, Naing Aung, Falchook Gerald S, Piha-Paul Sarina, Wheler Jennifer J, Fu Siqing, Tsimberidou Apostolia M, Stecher Michael, Mohanty Prasant, Simard John and Kurzrock Razelle. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. : The Lancet. Oncology. 20140623.